Previous PostJune 13, 2025: MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
Next PostJune 6, 2025: Biothérapie : le lyonnais MaaT Pharma franchit un cap avec son traitement à base de microbiote - La Tribune (French Only)